Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Beveridge

Showing results (71-80 of 77) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 77 results.
American Journal of Respiratory and Critical Care Medicine|January 20, 2009
Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individualsClare R Sander, Ansar A Pathan, Natalie E R Beveridge, et al.
Tuberculosis (Edinburgh, Scotland)|September 20, 2008
A comparison of IFNgamma detection methods used in tuberculosis vaccine trialsNatalie E R Beveridge, Helen A Fletcher, Jane Hughes, et al.
Urologic Oncology|March 23, 2017
The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal, and cognitive effects associated with androgen deprivation therapyE David Crawford, Andrew V Schally, Jehonathan H Pinthus, et al.
Clinical and Vaccine Immunology : CVI|June 11, 2010
Establishment of an aerosol challenge model of tuberculosis in rhesus macaques and an evaluation of endpoints for vaccine testingS A Sharpe, H McShane, M J Dennis, et al.
European Journal of Immunology|October 20, 2007
Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populationsNatalie E R Beveridge, David A Price, Joseph P Casazza, et al.
Canadian Respiratory Journal|May 22, 2001
What is new since the last (1999) Canadian Asthma Consensus Guidelines?L P Boulet, T R Bai, A Becker, et al.
BMJ Open|November 22, 2011
A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adultsAngela M Minassian, Rosalind Rowland, Natalie E R Beveridge, et al.
Pageof 8

Showing results (71-80 of 77) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 77 results.
American Journal of Respiratory and Critical Care Medicine|January 20, 2009
Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individualsClare R Sander, Ansar A Pathan, Natalie E R Beveridge, et al.
Tuberculosis (Edinburgh, Scotland)|September 20, 2008
A comparison of IFNgamma detection methods used in tuberculosis vaccine trialsNatalie E R Beveridge, Helen A Fletcher, Jane Hughes, et al.
Urologic Oncology|March 23, 2017
The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal, and cognitive effects associated with androgen deprivation therapyE David Crawford, Andrew V Schally, Jehonathan H Pinthus, et al.
Clinical and Vaccine Immunology : CVI|June 11, 2010
Establishment of an aerosol challenge model of tuberculosis in rhesus macaques and an evaluation of endpoints for vaccine testingS A Sharpe, H McShane, M J Dennis, et al.
European Journal of Immunology|October 20, 2007
Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populationsNatalie E R Beveridge, David A Price, Joseph P Casazza, et al.
Canadian Respiratory Journal|May 22, 2001
What is new since the last (1999) Canadian Asthma Consensus Guidelines?L P Boulet, T R Bai, A Becker, et al.
BMJ Open|November 22, 2011
A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adultsAngela M Minassian, Rosalind Rowland, Natalie E R Beveridge, et al.
Pageof 8